NASDAQ: BLRX

BioLineRx Ltd.

罗森律师事务所宣布一项代表在2021年2月23日至2022年9月19日期间购买了BioLineRx Ltd. (NASDAQ: BLRX) 股票的证券投资者,对该公司提起证券集体诉讼。该集体诉讼已经向法院提起。如果您希望担任首席原告,您必须在2023年3月6日前向法院申请。

如果您在诉讼期间购买了BioLineRx 股票,并且您想参加此次集体诉讼的话,请点击“加入此集体行动”键。

 

Class Period:February 23, 2021 through September 19, 2022
如果您在集体诉讼期间购买了 BioLineRx 证券,您可能有权获得赔偿,而无需支付任何自付费用或通过应急费用安排产生的费用。

Details of the case:

根据案件描述,被告在整个集体诉讼期间向投资者发布了虚假和/或误导声明和/或没有披露:

  • 该公司在推进其他发展计画的同时开发 Motixafortide 的资金不足;
  • BioLine 将需要从 Kreos Capital VII Aggregator SCSP 进行共计本金数额高达 4000 万美元的贷款,之后还需要发行 1500 万美元的证券以推进 Motixafortide 上市; 及
  • 因此,被告在所有相关时间就其业务、营运及前景所作之陈述,存在重大虚假和误导性和/或缺乏合理依据。

法院尚未确认本案为集体诉讼案件。在法院确认本案为集体诉讼之前,除非您自己个人亲自聘请律师,您没有代理律师。您可以自由选择您要聘请的律师。您也可以继续作为缺席的集体诉讼成员,目前不采取任何行动。投资者在未来任何可能赔偿中的分成金额大小与其是否作为首席原告无关。

律师广告。此前结果并不能保证类似的结果。

 

Follow us on:
Company Name: BioLineRx Ltd.
Stock Symbol: BLRX
Class Period: February 23, 2021 through September 19, 2022
Court: United States District Court District of New Jersey

Why Rosen Law

The Rosen Law Firm has been ranked among the top 4 law firms each year since 2013 for the number of successful securities class actions on behalf of investors. In 2019 alone, our firm recovered $438 million for investors.

Investors should carefully identify and select experienced counsel with a track record of success leading securities class actions. Often other firms issue press releases about class actions yet do not have comparable experience or resources.

Institutional Shareholders Services ranked the Rosen Law Firm # 1 for the number of securities class action recoveries in 2017.

The Rosen Law Firm represents investors throughout the globe. Our mission is to prosecute securities fraud class actions and protect shareholders’ rights.

Scroll to Top